Professional Documents
Culture Documents
Rutendo Kuwana
2|
Manufacturing site(s)
Name and street address of each facility where any aspect of manufacture occurs including production, sterilisation, packaging and quality control
Blocks and Units should be clearly stated Including any alternative manufacturers
Certificate issued by the Competent DRA according to WHO Certification scheme for each site where a major step of manufacturing is performed
3|
Pre- formulation
Formulation
Pilot manufacture
Industrial Scale
4|
Assessment of Interchangeable Multisource Medicines, Kenya, August 2009
Process evaluation and validation should justify reduction of some tests from routine
5|
Assessment of Interchangeable Multisource Medicines, Kenya, August 2009
Scale Up Data Used to generate information from laboratory through pilot to production scale batch Evidence that scale up will not result in loss in quality
Should show that variations in batch size will not adversely alter FPP characteristics
6|
7|
8|
Intermediates isolated during process e.g tablet cores in film-coated tablet production
Acceptance criteria (justified if not Compendial) Test methods (cross reference acceptable)
9|
Friability
Disintegration time Yield
Eur. Ph
Eur. Ph By weighing
1%
15min 97-100%
10 |
100/270mg Tablets
421- 447mg
679 - 721mg Round, biconvex, bilayered tablet; one layer is yellow coloured and may be mottled, and the other one is white to slightly yellow, with a break line, engraved "GP" on one side, and "100" on the other side
Thickness Hardness
4.1-4.4mm >100N
11 |
Process validation is the collection and evaluation of data, from process design stage throughout production, which establishes scientific evidence that a process is capable of consistently delivering quality products
US FDA
12 |
Established FPPs
The manufacturer has manufactured & marketed this FPP for quite some time Submit review of report for 10 recent consecutive batches Manufactured within the preceding year. If less than 10 batches, may extend the period to 3 years result/trend/statistical analysis & discussion Rejected batches excluded - submit failure investigation
13 |
Assessment of Interchangeable Multisource Medicines, Kenya, August 2009
13
Any aspect of operation, including significant changes to the premises, facilities, equipment or processes, which may affect the quality of the product, directly or indirectly, should be qualified and validated
14 |
15 |
16 |
17 |
18 |
18
19 |
19
Pilot batches
Used e.g. in stability and safety/efficacy studies Size for oral solid dosage forms: the largest of 10% of production scale or 100,000 units
Productions scale
For full validation and stability studies Scale-up / scale down after registration Up to10-fold compared to the original batch size (minor amendment/change)
20 |
20
Important to link development and evaluation of laboratory and pilot scale batches, process development and optimisation
21 |
21
To outline the formal validation process to be conducted on production scale batches (at least 3 consecutive batches) Data should be available for verification post registration
22 |
22
23
Certificates of analysis
Batch manufacturing records
Report on unusual findings, modifications or changes found necessary with appropriate rationale
Conclusions Significant deviations to be informed to DRA and regulatory approval required before implementation
24 |
Assessment of Interchangeable Multisource Medicines, Kenya, August 2009
24
Other requirements
For well-established processes/product for the manufacturer report on review of NLT 10 batches manufactured in the past 12 months
25 |
Review report for established FPP should contain at least the following
List of reviewed batches - batch numbers, manufacturing dates and batch size. Any differences from the prequalified/approved batch size should be clarified. Review of starting materials (active pharmaceutical ingredients (APIs) and excipients) list of sources (API), compliance with specifications Review of primary packing materials used in the FPP, including reference to those from new sources. A tabulation of Batch Analysis data (including in-process test results and finished product quality control results) together with statistical and trend analysis where appropriate. A review of all out-of-specification and related investigations, with indication of batches that failed to meet specification(s) A review of all deviations. All changes carried out Quality-related returns, complaints and recalls.
26 |
Alternatives
If validation data (on production scale batches) are not available submit
validation protocol,
commitment that validation report will be submitted later for evaluation, commitment that data will be available in case of inspection,
27 |
Analytical Methods
Process knowledge depends on accurate and precise measuring techniques on starting material, intermediates and finished product.
For data to be of value the analytical tests must be scientifically sound Validated analytical methods are not required during product and process development activities. The methods should however be scientifically sound (e.g. specific, sensitive, accurate), suitable and reliable for the specified purpose.
28 |
Assessment of Interchangeable Multisource Medicines, Kenya, August 2009
Pharmaceutical
To develop a stable and reproducible formulation for the manufacture of bioequivalence, dissolution, stability and pilot-scale validation batches
Methods
To understand the profile of related substances and to study stability and start measuring the impact of key product and manufacturing process parameters on consistent FPP quality
To optimize, scale-up, and transfer a stable and controlled manufacturing process for the prequalification product
To be robust, transferable, accurate, and precise for specification setting, stability assessment, and QC release of prequalified batches